S100A9 tetramers, which are ligands of CD85j, increase the ability of MVAHIV-primed NK cells to control HIV infection - Archive ouverte HAL Access content directly
Journal Articles Frontiers in Immunology Year : 2015

S100A9 tetramers, which are ligands of CD85j, increase the ability of MVAHIV-primed NK cells to control HIV infection

(1) , (1) , (2, 3) , (1) , (1)
1
2
3

Abstract

Natural killer (NK) cells are the major antiviral effector population of the innate immune system. We previously found that S100A9 is a novel ligand of the receptor CD85j and that S100A9 tetramers enhance the anti-HIV activity of NK cells. Also, we found that dendritic cells (DCs) infected by the HIV vaccine candidate, MVAHIV, prime NK cells to specifically control HIV infection in autologous CD4(+) T cells. In this study, we analyzed whether stimulation of NK cells by S100A9 tetramers prior to the priming by MVAHIV-infected DCs modulates the subsequent anti-HIV activity of NK cells. We found that S100A9 tetramers activate NK cells and that DCs enhance the anti-HIV activity of NK cells. Interestingly, we observed that stimulation of NK cells by S100A9 tetramers, prior to the priming, significantly increased the subsequent anti-HIV activity of NK cells and that the enhanced anti-HIV activity was observed following different conditions of priming, including the MVAHIV-priming. As S100A9 tetramers alone directly increase the anti-HIV activity of NK cells and as this increased anti-HIV activity is also observed following the interaction of NK cells with MVAHIV-infected DCs, we propose S100A9 tetramers as potential adjuvants to stimulate the anti-HIV activity of NK cells.
Fichier principal
Vignette du fichier
fimmu-06-00478.pdf (1.58 Mo) Télécharger le fichier
Loading...

Dates and versions

pasteur-02573697 , version 1 (14-05-2020)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Uriel Moreno-Nieves, Céline Didier, Yves Levy, Françoise Barré-Sinoussi, Daniel Scott-Algara. S100A9 tetramers, which are ligands of CD85j, increase the ability of MVAHIV-primed NK cells to control HIV infection. Frontiers in Immunology, 2015, 6, pp.478. ⟨10.3389/fimmu.2015.00478⟩. ⟨pasteur-02573697⟩
31 View
32 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More